Wendel-Garcia, PD, Mas, A, Gonzalez-Isern, C, Ferrer, R, Manez, R, Masclans, JR, Sandoval, E, Vera, P, Trenado, J, Fernandez, R, Sirvent, JM, Martinez, M, Ibarz, M, Garro, P, Lopera, JL, Bodi, M, Yebenes-Reyes, JC, Triginer, C, Vallverdu, I, Baro, A, Bodi, F, Saludes, P, Valencia, M, Roche-Campo, F, Huerta, A, Cambra, FJ, Barbera, C, Echevarria, J, Penuelas, O, Mancebo, J, UCIsCAT Study Grp. Non-invasive oxygenation support in acutely hypoxemic COVID-19 patients admitted to the ICU: a multicenter observational retrospective study. CRITICAL CARE. 2022; 26(1)DOI:10.1186/s13054-022-03905-5. PMID:35135588. IF:15.100(Q1/2D).

Pinana, JL, Garcia-Sanz, R, Martino, R, Garcia-Rao, M, Martin-Martin, GA, Risco-Galvez, I, Tormo, M, Martinez-Barranco, P, Marcos-Corrales, S, Calabuig, M, Conesa, V, Teruel, A, Ruiz-Perez, S, Solano, C, Navarro, D, Cedillo, A, Sureda, A. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021006326. PMID:34905620. IF:7.500(Q1/2D).

Onate, G, Bataller, A, Garrido, A, Hoyos, M, Arnan, M, Vives, S, Coll, R, Tormo, M, Sampol, A, Escoda, L, Salamero, O, Garcia, A, Bargay, J, Aljarilla, A, Nomdedeu, JF, Esteve, J, Sierra, J, Pratcorona, M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2020004136. PMID:34516636. IF:7.500(Q1/2D).

Menghrajani, K, Gomez-Arteaga, A, Madero-Marroquin, R, Zhang, MJ, Bo-Subait, K, Sanchez, J, Wang, HL, Aljurf, M, Assal, A, Bacher, VU, Badawy, SM, Bejanyan, N, Bhatt, VR, Bredeson, C, Byrne, M, Castillo, P, Cerny, J, Chhabra, S, Ciurea, SO, DeFilipp, Z, Farhadfar, N, Gadalla, S, Gale, RP, Ganguly, S, Gowda, L, Grunwald, MR, Hashmi, S, Hildebrandt, G, Kanakry, CG, Kansagra, A, Khimani, F, Krem, M, Lazarus, H, Liu, HT, Martino, R, Michelis, FV, Nathan, S, Nishihori, T, Olsson, R, Reshef, R, Rizzieri, D, Rowe, JM, Savani, BN, Seo, S, Sharma, A, Solh, M, Ustun, C, Verdonck, LF, Hourigan, C, Sandmaier, B, Litzow, M, Kebriaei, P, Weisdorf, D, Zhang, YM, Tallman, MS, Saber, W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021004881. PMID:34551064. IF:7.500(Q1/2D).

Rioja-Blanco, E, Arroyo-Solera, I, Alamo, P, Casanova, I, Gallardo, A, Unzueta, U, Serna, N, Sanchez-Garcia, L, Quer, M, Villaverde, A, Vazquez, E, Leon, X, Alba-Castellon, L, Mangues, R. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2022; 41(1)DOI:10.1186/s13046-022-02267-8. PMID:35120582. IF:11.300(Q1/1D).

Cortes-Vicente, E, Alvarez-Velasco, R, Pla-Junca, F, Rojas-Garcia, R, Paradas, C, Sevilla, T, Casasnovas, C, Gomez-Caravaca, MT, Pardo, J, Ramos-Fransi, A, Pelayo-Negro, AL, Gutierrez-Gutierrez, G, Turon-Sans, J, de Munain, AL, Guerrero-Sola, A, Jerico, I, Martin, MA, Mendoza, MD, Moris, G, Velez-Gomez, B, Garcia-Sobrino, T, Pascual-Goni, E, Reyes-Leiva, D, Illa, I, Gallardo, E. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Annals of Clinical and Translational Neurology. 2022; 9(2)DOI:10.1002/acn3.51492. PMID:35080153. IF:5.300(Q1/2D).